Plain-English translation of NCT06966024 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called designed to treat advanced forms of three cancers: renal cell carcinoma (kidney cancer), urothelial carcinoma (bladder cancer), and castration-resistant prostate cancer. Researchers want to understand how safe this medication is and how well it works. The study will gradually increase the dose to find the right amount that helps without causing too many side effects.
Current treatments for these advanced cancers don't work well for everyone, and doctors need new options. This medication targets a specific pathway in cancer cells, and early research suggests it might help slow or stop cancer growth in people whose cancers have stopped responding to other treatments.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth as a daily pill, starting at a lower dose that may be gradually increased based on how your body responds and any side effects you experience. You'll visit the clinic regularly for blood tests, physical exams, and scans to monitor how you're tolerating the medication and whether your cancer is responding. The trial is designed to learn about safety first, so you'll be watched closely for any side effects throughout your participation.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States